Migraine drug AJOVY under Real-World safety spotlight
NCT ID NCT05342493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks about 1,000 people with migraine who are taking AJOVY (fremanezumab) as part of their regular care. The goal is to see how safe the drug is over the long term, especially regarding heart problems. Researchers will also collect information on how well it works. The study does not assign treatment—it simply observes what happens in everyday use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fremanezumab (AJOVY)
- What this could lead to
- If successful, this study could confirm that AJOVY is safe for long-term use and help doctors better manage migraine treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may show unexpected side effects or no clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pharmacovigilance Department
RECRUITINGOsaka, 540-0021, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted botox shot quiet the Brain's pain center for chronic migraine?
- Could a symptom registry unmask hidden migraine variants?
- Melatonin may double up against childhood migraines
- Online sleep therapy may ease migraines in teens
- Scientists aim to forecast migraine pain using wearable sensors and early symptoms
- New online tool helps teens fight migraines